Last updated: April 25, 2026
What are the investment drivers and fundamentals for OPTIRAY 320 (iopromide)?
OPTIRAY 320 is a brand of iopromide, a low-osmolar, non-ionic iodinated contrast medium used in CT and angiography. It sits in the mature, procedure-linked radiology spend segment. Investment case quality depends less on patent-led growth and more on (1) documented volume stability in imaging workflows, (2) competitive pricing of generic/authorized-licensed equivalents, (3) regulatory and supply reliability, and (4) payer reimbursement dynamics.
What is OPTIRAY 320 and how does it make money?
Product scope and standard usage profile
- Active ingredient: iopromide
- Strength/concentration: 320 mg I/mL
- Dosage form: Injectable iodinated contrast for imaging
- Typical clinical positioning: Radiographic contrast for CT and other angiographic/radiology applications where iodinated contrast is used
Core value proposition in procurement
Across imaging systems, iopromide products compete on:
- Clinical acceptability (contrast enhancement performance; tolerability profile in routine use)
- Supply continuity (ready availability to avoid scanner downtime)
- Pack configuration and unit economics (vials vs pack sizes; dose-to-dose cost)
- Contracting (hospital group purchasing, tender cycles, and formulary placement)
How mature is the category, and what does that imply for growth?
Competitive structure
Iodinated contrast media is a mature category with multiple suppliers and frequent generic entry. Growth typically comes from:
- imaging volume growth (scanner utilization, procedure volumes)
- contract share shifts through tendering
- pack and portfolio breadth (multiple concentrations, container sizes)
Price growth tends to be capped by:
- generic/authorized product competition
- tender pressure in hospital procurement
- reimbursement constraints
Implication for investors
A brand like OPTIRAY 320 generally behaves like:
- share-and-contract income rather than
- platform or pipeline upside
What do the fundamentals look like: demand, risks, and durability?
Demand drivers (non-patent)
Demand tracks with:
- CT utilization (volume of cross-sectional imaging)
- Hospital imaging network capacity (how many scanners are operating and scheduled)
- Dose intensity (protocol-driven iopromide usage per scan)
- Seasonality and throughput (procedure scheduling impacts monthly volumes)
Key operational risks (material for supply-linked drugs)
- Manufacturing continuity: contrast media are production-sensitive and distribution-sensitive.
- Regulatory inspection outcomes: quality and sterility controls are table stakes.
- Market withdrawals: any supply interruption can cause immediate contract switching.
Reimbursement and contracting
- Contrast media are often procured under hospital group contracts, with pricing reset during tenders.
- Product selection can shift quickly if an alternative is priced lower with equivalent accepted specifications.
What does the patent and exclusivity landscape likely mean for valuation?
OPTIRAY 320’s iopromide active is long established. In investment terms, this means valuation typically does not hinge on long runway from active patent protection at the molecule level. Instead, the defensibility usually comes from:
- brand-level manufacturing and regulatory history
- line extensions or specific packaging
- authorized generics and supply chain arrangements
Practical impact:
- downside is driven by contract price compression
- upside is driven by share wins and stable procurement pricing
Where does OPTIRAY 320 sit versus alternatives?
Competitive set
OPTIRAY 320 competes primarily with other iodinated low-osmolar non-ionic contrast agents and with authorized/generic equivalents of iopromide.
Typical differentiators used in procurement
Hospitals select based on:
- tender price and contract terms
- clinical protocol compatibility with radiology department standards
- pack sizes and dosing workflow
- local supply reliability
What are the measurable business fundamentals to track?
Commercial KPIs (what moves revenues in this category)
Use these as the core diligence metrics:
- Unit volumes (vials/bottles shipped) tied to imaging procedure volumes
- Net price realization vs list price (tender and contract effects)
- Share in CT contrast workflows in assigned hospital networks
- Inventory and lead times (supply stability)
- Switching frequency across tender cycles
Financial KPIs (what signals risk or opportunity)
- Gross margin trend under competitive price pressure
- Working capital linked to supply and stocking patterns
- Cost of goods stability (manufacturing scale utilization)
- Receivables and chargebacks tied to contract terms
Investment scenario: base case, bull case, bear case
Base case (most likely for mature contrast brands)
- Imaging volumes grow in line with healthcare utilization trends.
- Price erosion continues modestly under competitive pressure.
- Share remains stable in existing contracted networks.
Expected profile: steady revenue, margin gradual compression, limited upside from exclusivity.
Bull case (share and contracting outperformance)
- OPTIRAY 320 wins tender share in targeted hospital systems due to pricing and supply reliability.
- Fewer disruptions than competing suppliers.
- Net price holds better than category average.
Expected profile: unit growth outpaces category and margins stabilize relative to peers.
Bear case (contract repricing and supply disruptions)
- Aggressive tendering from authorized/generic equivalents reduces net price faster than expected.
- Supply interruption triggers contract switching.
- Demand shift to alternate contrast protocols or competitor procurement changes.
Expected profile: revenue contraction or flat growth with faster margin decline.
How to benchmark OPTIRAY 320 against peer performance
Benchmarking approach (actionable for analysts)
Compare OPTIRAY 320 against:
- iodinated contrast peer brands on net sales growth and margin trajectory
- competitors on tender wins and portfolio coverage (concentration and pack sizes)
- generic penetration signals (presence, pricing, and volume share shifts)
What you should expect in mature markets
- Generic/authorized pressure compresses pricing.
- Volume growth does not fully offset price erosion without share gains.
- Claims of superiority are usually secondary to procurement economics.
What diligence artifacts typically matter most for decision-making?
- Regulatory approvals and labeling scope (indications and dosing language)
- Manufacturing quality records (inspection outcomes, recalls, batch issues)
- Contracting footprint (which hospital groups and whether terms reset annually or multi-year)
- Supply chain stability (fill rate, lead time performance)
- Portfolio strategy (multiple pack formats; any bundling or conversion programs)
Key Takeaways
- OPTIRAY 320 is a mature, procedure-linked radiology product where investment outcomes track imaging utilization, tender-driven net pricing, and contract share, not molecule-level innovation.
- The category’s economics favor suppliers that manage supply reliability and maintain net price realization through hospital group contracting.
- The highest-impact diligence variables are unit volume, net price/margin trend, tender cycle outcomes, and manufacturing continuity.
- Upside is share-and-contract outperformance; downside is faster-than-category price compression and any supply disruption.
FAQs
1) What is OPTIRAY 320 used for?
OPTIRAY 320 is iopromide (320 mg I/mL) used as an injectable iodinated contrast medium for radiology imaging, including CT and angiography workflows.
2) What drives OPTIRAY 320 demand?
Demand is primarily driven by CT and other imaging procedure volumes, driven by scanner utilization and clinical protocol dosing patterns.
3) Is OPTIRAY 320 a patent-led growth story?
No. The iopromide molecule is long established, so the business case is typically driven by contracting, procurement economics, and supply continuity rather than new patent runway.
4) How does competition typically affect OPTIRAY 320 pricing?
Competition from other iodinated contrast products and authorized/generic equivalents typically compresses net pricing during tender cycles and contract renegotiations.
5) What should an investor monitor most closely?
Monitor unit volume trends, net price realization, gross margin trajectory, tender-share movement, and supply reliability indicators.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug label information for iodinated contrast media (iopromide). https://www.accessdata.fda.gov/
